Management ChangeJul 13, 2026, 07:01 AM
Adlai Nortye Expands Scientific Advisory Board with Two Appointments
AI Summary
Adlai Nortye Ltd. announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Dr. David S. Hong and Dr. Piro Lito. These leading medical oncologists will provide critical scientific guidance to shape the company's R&D strategy and clinical development priorities. Their expertise in clinical development, translational oncology, RAS biology, and targeted therapeutic strategies is expected to support the advancement of Adlai Nortye's innovative cancer therapies.
Key Highlights
- Adlai Nortye expanded its Scientific Advisory Board (SAB) with two new appointments.
- Dr. David S. Hong, a leading translational and clinical development expert, joined the SAB.
- Dr. Piro Lito, a pioneer in targeted treatment of RAS-driven cancers, also joined the SAB.
- The new members will provide scientific guidance for the company's R&D strategy and clinical development.
- Adlai Nortye's pipeline includes RAS inhibitor programs AN9025 and AN4035, and immuno-oncology candidate AN8025.
Price Impact
More from ANL